|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C21H24N2O2 |
|||
| Molecular Weight | 336.43 | CAS No. | 1197996-80-7 | |
| Solubility (25°C)* | In vitro | DMSO | 15 mg/mL (44.58 mM) | |
| Ethanol | 8 mg/mL (23.77 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
Protocol (from reference)
Selleck's CBL0137 has been cited by 8 publications
| New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline [ Cancer Med, 2024, 13(20):e70288] | PubMed: 39440923 |
| SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis [ JCI Insight, 2023, 8(4)e154120] | PubMed: 36810256 |
| CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells [ Biomed Pharmacother, 2023, 161:114529] | PubMed: 37002567 |
| SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes [ Nat Cancer, 2022, 3(2):188-202] | PubMed: 35115713 |
| Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation [ Cancer Lett, 2021, 520:201-212] | PubMed: 34271103 |
| The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma [ Cancer Lett, 2021, 499:232-242] | PubMed: 33253788 |
| HeLa TI cell-based assay as a new approach to screen for chemicals able to reactivate the expression of epigenetically silenced genes [ PLoS One, 2021, 16(6):e0252504] | PubMed: 34115770 |
| Chromatin Trapping of Factors Involved in DNA Replication and Repair Underlies Heat-Induced Radio- and Chemosensitization [ Cells, 2020, 9(6):1423] | PubMed: 32521766 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.